Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.60 |
| ▸ | TACR1 | P25103 | 1/20 | 0.60 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18775048 | 1.00 | CTSK (0.60) | CTSKTACR1S1PR4S1PR1ALDH1A1 | |
| SCHEMBL11432342 | 0.90 | CTSK (0.61) | CTSKS1PR4S1PR1ALDH1A1CTSS | |
| SCHEMBL11764262 | 0.90 | CTSK (0.58) | CTSKTACR1S1PR4S1PR1ALDH1A1 | |
| SCHEMBL11764270 | 0.90 | CTSK (0.58) | CTSKTACR1S1PR4S1PR1ALDH1A1 | |
| SCHEMBL16272916 | 0.88 | CTSK (0.76) | CTSKCTSSCTSLCTSB | |
| SCHEMBL18775040 | 0.87 | CTSK (0.62) | CTSKS1PR4S1PR1CTSSCTSL | |
| SCHEMBL18791072 | 0.87 | CTSK (0.62) | CTSKS1PR4S1PR1CTSSCTSL | |
| SCHEMBL10421048 | 0.86 | CTSK (0.60) | CTSKS1PR4S1PR1CTSSCTSL | |
| SCHEMBL18775036 | 0.86 | CTSK (0.57) | CTSKS1PR4S1PR1ALDH1A1CTSS | |
| SCHEMBL18790940 | 0.86 | CTSK (0.63) | CTSKS1PR4S1PR1ALDH1A1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116370448-A | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| CN-110809467-B | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-110809467-A | Modulators of SESTRIN-GATOR2 interaction and uses thereof | 纳维托制药有限公司 | 2020-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | CTSK 4783/4885TACR1 1097/4885S1PR4 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.